Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2178MR)

This product GTTS-WQ2178MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2178MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11479MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ15529MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ4678MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ13321MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ2117MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ153MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ5051MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW